“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
GOTEMBURGO, Sweden, 10 July 2020 / PRNewswire / – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), reports that the COVID-19 outbreak has affected the overall scenario of THE AGENT’s examination activities. Patient recruitment continued uninterrupted during the pandemic, however, the effects of COVID-19 can result in a delay in full recruitment of up to 3 months.
As hospitals, regions and countries have updated their guidelines, Isofol has adapted accordingly to fully comply with the new procedures. To ensure continuity of the existing AGENT exam in a guilty manner, the company has implemented a number of proactive measures and works largely with local fitness governance on an ongoing basis.
Ulf Jungnelius, MD, CEO of Isofol, commented: “Since the outbreak of the COVID-19 pandemic, Isofol’s most sensible priority has been to ensure the protection of patients, health professionals, workers and providers involved in the AGENT exam. proud to have temporarily made a successful transition to virtual patient monitoring. To date, we are reaching 330 patients with the overall goal of examining 440 patients needed. However, the effect of COVID-19 has caused a slowdown in recruitment speed, which can delay full enrollment by up to 3 months. Our next step, interim research of 330 patients, is expected to begin in the third quarter of 2020.”
Isofol continues to largely monitor progression and has a close conversation with all stakeholders to recruit patients in accordance with regulatory rules and site capabilities. More than 90 sites in the United States, Canada, Europe, Australia and Japan are recruiting patients on the AGENT test who will get a first-line remedy for metastatic colorectal cancer (CCRm).
For information, contact
Isofol Medical AB (publ) Jarl Ulf Jungnelius, M.D., General Manager Email: [email protected] Phone: (0) 709 89 55
FNCA Certified ADVISOR Sweden ABE-mail: [email protected] Phone: (0) 8528003 99
The data sent for publication, through the touch user mentioned above, at 15:00 CET on July 10, 2020.
About arfolitixorina
Arfolitixorine is the only isofol drug candidate in progression to increase the effectiveness of popular attention chemotherapy for complex colorectal cancer. The candidate drug is currently being studied as a component of a global phase 3 study, AGENT. As a key active metabolite of widely used folate-based drugs, arfolitixorin can potentially gain advantages for all patients with complex colorectal cancer, as it does not require confusing metabolic activation to be effective.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinically evolved biotechnology company that approaches arfolitixorina with the effectiveness of popular attention chemotherapy for complex colorectal cancer by expanding tumor reaction and progression-free survival. Isofol has an exclusive global licensing agreement with Merck KGaA, Darmstadt, Germany to expand and market arfolitixorine for oncology indications. Isofol Medical AB (publ) is indexed on the Nasdaq First North Premier Growht Market. The qualified advisor is FNCA Sweden AB.
www.isofolmedical.com
This data was provided to you through Cision http://news.cision.com
https://news.cision.com/isofol-medical-ab–publ-/r/agent-study-update-with-regards-to-covid-19,c3152325
The following files are available for download:
https://mb.cision.com/Main/15598/3152325/1277744.pdf
Launch
View content: http://www.prnewswire.com/news-releases/agent-study-update-with-regards-to-covid-19-301091584.html
SOURCE Isofol Medical AB (publ)